BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

Stephen B Hanauer  1     Stefan Schreiber  2     Sigrid Balser  3     Ekkehard Brockstedt  4     Dorothy McCabe  5     Viktoria Moschetti  5     Bernd Liedert  6    
1 Feinberg School of Medicine, Northwestern University, Chicago, United States
2 Department Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany
3 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
4 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
5 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States
6 Former employee of Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing